Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 11Leucovorin 10Oxaliplatin 9Bevacizumab 6Irinotecan 5Capecitabine 3regorafenib 2aflibercept 2Folfox protocol 2Exercise 2Chemotherapy, Adjuvant 2Cetuximab 2Biopsy 2Atorvastatin 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1sulindac sulfone 1sargramostim 1retrovector encoding mutant anti-cyclin G1 1poly ICLC 1pidilizumab 1pembrolizumab 1p53 peptide 264-272, human 1nilotinib 1monalizumab 1lonafarnib 1irofulven 1infigratinib 1grp protein, Drosophila 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colonic Neoplasms × Yttrium-90 × Clear all
NCT00766220 2013-01-03

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡